US 12,383,521 B2
Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
Roshantha A. Chandraratna, San Juan Capistrano, CA (US); Ethan Dmitrovsky, Hanover, NH (US); Elizabeth Nowak, West Lebanon, NH (US); Randolph Noelle, Plainfield, NH (US); and Martin E. Sanders, Spring, TX (US)
Assigned to Io Therapeutics, Inc, Spring, TX (US); and Trustees of Dartmouth College, Hanover, NH (US)
Filed by Io Therapeutics, Inc., Spring, TX (US); and Trustees of Dartmouth College, Hanover, NH (US)
Filed on Jul. 7, 2022, as Appl. No. 17/859,743.
Application 17/859,743 is a continuation of application No. 16/736,705, filed on Jan. 7, 2020, abandoned.
Application 16/736,705 is a continuation of application No. 14/507,730, filed on Oct. 6, 2014, granted, now 10,653,650, issued on May 19, 2020.
Application 14/507,730 is a continuation in part of application No. 13/714,051, filed on Dec. 13, 2012, abandoned.
Claims priority of provisional application 61/887,529, filed on Oct. 7, 2013.
Claims priority of provisional application 61/570,182, filed on Dec. 13, 2011.
Prior Publication US 2022/0370386 A1, Nov. 24, 2022
Int. Cl. A61K 31/192 (2006.01); A61K 31/216 (2006.01); A61K 31/343 (2006.01); A61K 31/353 (2006.01); A61K 31/47 (2006.01); A61K 31/4704 (2006.01); A61K 40/11 (2025.01)
CPC A61K 31/192 (2013.01) [A61K 31/216 (2013.01); A61K 31/343 (2013.01); A61K 31/353 (2013.01); A61K 31/47 (2013.01); A61K 31/4704 (2013.01); A61K 40/11 (2025.01)] 21 Claims
 
1. A method of generating T regulatory cells (Treg) in vitro comprising culturing lymphocytes in the presence of an RXR agonist, wherein the RXR agonist is a compound having the structure of formula XXIX:

OG Complex Work Unit Chemistry
and
wherein the concentration of formula XXIX is at least 0.1 nM.